AlphAIalphai — Financial news for AI agents
prnewswire.comAUG 262 min read$EYPT

EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky

EyePoint Pharmaceuticals (EYPT) shares fell ~70% after DURAVYU failed to meet the primary endpoint in the Phase 3 LUGANO trial for wet age-related macular degeneration. The company reported favorable secondary results, including a 42% reduction in treatment burden. Levi & Korsinsky is investigating potential securities fraud claims on behalf of EYPT investors who lost money.

Original reporting
prnewswire.com
Published Aug 26, 2026, 2:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 3:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky — source image
Source · prnewswire.com
Decision brief

The 30-second read

$EYPTBearishLow
01

Why it matters

The disclosure triggers a sharp price drop and may lead to further investor litigation, affecting valuation and sector sentiment.

02

Market read

Primary biotech news with immediate price impact; relevant for short‑term traders and sector risk managers.

03

What to watch

Potential for a follow‑up trial or partnership could mitigate the immediate fallout.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

EyePoint Pharmaceuticals announced a Phase 3 trial failure for its wet‑AMD drug DURAVYU, prompting a securities‑class‑action solicitation.

Company-level read

Ticker impact

$EYPTBearishHigh confidence
Context

EyePoint disclosed its Phase 3 LUGANO trial missed the primary endpoint, sending the stock down ~70% at open.

Expected impact

Expect continued downside pressure; potential further 10‑15% drop in coming days.

Evidence & confidence

Clinical‑trial miss is a primary driver of biotech valuations; no mitigating data offset the loss.

Market effects

Sector

Wet‑AMD biotech segment may see broader risk reassessment.

Regional

US biotech indices could dip modestly.

Global

Limited to investors tracking ocular‑therapy pipelines.

Counterpoint

What could challenge this read

If secondary endpoints hold commercial promise, the stock could rebound on long‑term potential.

Key entities

  • company
    EyePoint Pharmaceuticals

    NASDAQ‑listed biotech developing ocular therapies.

  • law_firm
    Levi & Korsinsky

    Securities litigation firm soliciting investors.

Read at source← All news

Related articles

AUG 18
$EYPTHighAI 9/10

EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal

EyePoint Pharmaceuticals (EYPT) reported that its phase III study for Duravyu in wet age-related macular degeneration (wet AMD) missed the primary endpoint, causing shares to drop 67%. The study did not show non-inferiority to Regeneron's (REGN) Eylea in the full dataset, but Duravyu met key secondary endpoints, including a 42% reduction in treatment burden. The company plans to present additional data and awaits results from a second phase III study, LUCIA, expected in Q4 2026. EYPT shares have

tradingview.com5 min
AUG 18
$EYPTMed

EyePoint’s Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says – Retail Calls EYPT Slump A ‘Huge Overreaction’

EyePoint Inc. (EYPT) shares fell again in pre-market after a Phase 3 wet AMD trial setback. RBC Capital downgraded EYPT to Sector Perform from Outperform and cut its price target about 86% to $5, citing Duravyu’s failure to meet the primary endpoint versus aflibercept. RBC and H.C. Wainwright said regulatory and clinical uncertainty could persist; results expected in Q4.

tradingview.com4 min
AUG 17
$EYPTHighAI 8/10

EyePoint's DURAVYU Phase 3 LUGANO Trial Misses Primary Endpoint; Stock Plunges

EyePoint (EYPT) reported topline Phase 3 LUGANO results for DURAVYU (vorolanib intravitreal insert) in wet AMD. The trial missed the primary endpoint versus aflibercept in the full dataset, but an ad hoc analysis excluding a small cohort showed non-inferiority (p=0.0096). Secondary results included a 42% treatment-burden reduction (p<0.0001). LUCIA data expected Q4 2026.

rttnews.com4 min
AUG 17
$EYPTMed

The Surprising Reason This Biotech Plummeted 69%

EyePoint (EYPT) shares fell about 69% after its Duravyu treatment for wet age-related macular degeneration missed the primary endpoint in a late-stage study, according to the company. Results cited include a 42% reduction in treatment burden and 56% of patients supplement-free by week 56, but the trial did not meet its main goal.

investors.com2 min